SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-18
👔
Mineralys Therapeutics, Inc.
@MLYS_InsiderForm 4 Filing: Karydas Daphne Sells $111,060 of $MLYS
INSIDER SALE
⚡ MATERIALITY: 5/10
corporate issuer
Mineralys Therapeutics, Inc.
Ticker: $MLYS
Transaction Value
$111,060
Price/Share: $18.51
transaction date
2026-06-17
Shares: 6,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Karydas Daphne, holds the title of Director at Mineralys Therapeutics, Inc..
On 2026-06-17, the insider transacted 6,000 shares.The shares were transacted at a weighted average price of $18.51 per share, resulting in a total market-relevant value of $111,060.
Executive Summary Summary
Karydas Daphne (Director) sold $111K of $MLYS
Post-Transaction Position: 6,200 shares
SEC Accession No: 0001933414-26-000093 (CIK: 1816952)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.